The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 4, 2007, Pages 1892-1899

  Mukherjee, Sudipto ^a,b   Guidry, Clyde ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN B; SOMATOMEDIN C;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FORCE; NONHUMAN; PATHOPHYSIOLOGY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; TISSUE CULTURE; VITREORETINOPATHY; VITREOUS BODY; ANIMAL; CELL ADHESION; CELL COUNT; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SWINE;

ANIMALS; CELL ADHESION; CELL COUNT; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; PIGMENT EPITHELIUM OF EYE; SWINE;

EID: 34248393072     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-1095     Document Type: Article

References (62)

1. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43:3-18.
2. Weller M, Wiedemann P, Heimann K. Proliferative vitreoretinopathy. Is it anything more than wound healing at the wrong place? Int Ophthalmol. 1990;14:105-117.
3. Girard P, Mimoun G, Karpouzas I, Montefiore G. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina. 1994;14:417-424.
4. Pastor JC, Rodriguez de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21:127-144.
5. Ryan SJ. The pathophysiology of proliferative vitreoretinopathy and its management. Am J Ophthalmol. 1985;100:188-193.
6. Cowley M, Conway B, Campochiaro P, Kaiser D, Gaskin H. Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol. 1989;107:1147-1151.
7. Machemer R. Proliferative vitreoretinopathy (PVR): a personal account of its pathogenesis and treatment. Invest Ophthalmol Vis Sci. 1988;29:1771-1783.
8. The Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90:121-125.
9. Charteris DG, Sethi CS, Lewis GP, Fisher SK. Proliferative vitreoretinopathy: developments in adjunctive treatment and retinal pathology. Eye. 2002;16:369-374.
10. Sebag J. Shaken not stirred: guest editorial. Ophthalmology. 2001;108:1177-1178.
11. Wiedemann P, Weller M. The pathophysiology of proliferative vitreoretinopathy. Acta Ophthalmol (Copenh). 1988;189:4-15.
12. Campochiaro PA. Pathogenesis of Proliferative Vitreoretinopathy. 3rd ed. St. Louis: Mosby; 2001:2221-2227.
13. Grierson I, Mazure A, Hogg P, Hiscott P, Sheridan C, Wong D. Non-vascular vitreoretinopathy: the cells and the cellular basis of contraction. Eye. 1996;10:671-684.
14. Baudouin C, Hofman P, Brignole F, Bayle J, Loubiere, Gastaud P. Immunocytology of cellular components in vitreous and subretinal fluid from patients with proliferative vitreoretinopathy. Ophthalmologica. 1991;203:38-46.
15. Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol. 1995;79:953-960.
16. Casaroli-Marano RP, Pagan R, Vilaro S. Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in RPE. Invest Ophthalmol Vis Sci. 1999;40:2062-2072.
17. Vinores SA, Campochiaro PA, Conway BP. Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. Invest Ophthalmol Vis Sci. 1990;31:14-28.
18. Grisanti S, Guidry C. Transdifferentiation of retinal pigment epithelial cells from epithelial to mesenchymal phenotype. Invest Ophthalmol Vis Sci. 1995;36:391-405.
19. Glaser BM, Cardin A, Biscoe B. Proliferative vitreoretinopathy: the mechanism of development of vitreoretinal traction. Ophthalmology. 1987;94:327-332.
20. Wong CA, Potter MJ, Cui JZ, et al. Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells. Can J Ophthalmol. 2002;37:211-220.
21. Peters MA, Burke JM, Clowry M, Abrams GW, Williams GA. Development of traction retinal detachments following intravitreal injections of retinal Muller and pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol. 1986;224:554-563.
22. Yang CH, Huang TF, Liu KR, Chen MS, Hung PT. Inhibition of retinal pigment epithelial cell-induced tractional retinal detachment by disintegrins, a group of Arg-Gly-Asp-containing peptides from viper venom. Invest Ophthalmol Vis Sci. 1996;37:843-854.
23. Grisanti S, Guidry C, Heimann K. Contraction of extracellular matrix by transdifferentiated retinal pigment epithelial cells, inducers and inhibitors (in German). Ophthalmologue. 1996;93:709-713.
24. Wiedemann P. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol. 1992;36:373-384.
25. Connor TB, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor beta type 2 levels in the eye. J Clin Invest. 1989;83:1661-1666.
26. Cassidy L, Barry P, Shaw C, Duffy J, Kennedy S. Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders. Br J Ophthalmol. 1998;82:181-185.
27. Guidry C, Feist R, Morris R, Hardwick CW. Changes in IGF activities in human diabetic vitreous. Diabetes. 2004;53:2428-2435.
28. Hardwick C, Feist R, Morris R, et al. Tractional force generation by porcine Müller cells: stimulation by growth factors in human vitreous. Invest Ophthalmol Vis Sci. 1997;38:2053-2063.
29. Guidry C. Tractional force generation by porcine Müller cells: development and differential stimulation by growth factors. Invest Ophthalmol Vis Sci. 1997;38:456-468.
30. Guidry C, Bradley KM, King JL. Tractional force generation by human Müller cells: growth factor responsiveness and integrin receptor involvement. Invest Ophthalmol Vis Sci. 2003;44:1355-1363.
31. Guidry C. The role of Müller cells in fibrocontractive retinal diseases. Prog Retin Eye Res. 2005;24:75-86.
32. Grant MB, Guay C, Marsh R. Insulin-like growth factor I stimulates proliferation, migration, and plasminogen activator release by human retinal pigment epithelial cells. Curr Eye Res. 1990;9:323-335.
33. Spraul CW, Kaven C, Amann J, Lang GK, Lang GE. Effect of insulin-like growth factors 1 and 2, and glucose on the migration and proliferation of bovine retinal pigment epithelial cells in vitro. Ophthalmic Res. 2000;32:244-248.
34. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol. 2000;278:E967-E976.
35. Duan C, Xu Q. Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. Gen Comp Endocrinol. 2005;142:44-52.
36. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23:824-854.
37. Conover CA. Regulation and physiological role of insulin-like growth factor binding proteins. Endocr J. 1996;43:S43-S48.
38. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3-34.
39. King JL, Guidry C. Insulin-like growth factor binding proteins modulate Müller cell responses to insulin-like growth factors. Invest Ophthalmol Vis Sci. 2004;45:2848-2855.
40. Burgos R, Mateo C, Canton A, Hernandez C, Mesa J, Simo R. Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. Diabetes Care. 2000;23:80-83.
41. Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease: studies in nondiabetic and diabetic subjects. J Clin Invest. 1993;92:2620-2625.
42. Spranger J, Buhnen J, Jansen V, et al. Systemic levels contribute significantly to increased intraocular IGF- I, IGF-II and IGF-BP3 [correction of IFG-BP3] in proliferative diabetic retinopathy. Horm Metab Res. 2000;32:196-200.
43. Waldbillig RJ, Jones BE, Schoen TJ, et al. Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics. Curr Eye Res. 1994;13:539-546.
44. Hopkins KD, Brart DO, Russell-Jones DL, Chignell AH, Sonsken PH. Insulin-like growth factor binding protein-1 levels in diabetic proliferative retinopathy. Horm Metab Res. 1993;25:331-332.
45. Mamballikalathil I, Mann C, Guidry C. Tractional force generation by porcine Müller cells: paracrine stimulation by retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2000;41:529-536.
46. Miller E, Rhodes R. Preparation and characterization of the different types of collagen. Methods Enzymol. 1982;82:33-64.
47. Francis GL, Aplin SE, Milner SJ, McNeil KA, Ballard FJ, Wallace JC. Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II. Biochem J. 1993;293:713-719.
48. 3, following their expression in Escherichia coli as fusion proteins. J Mol Endocrinol. 1992;8:29-41.
49. King JL, Guidry C. Müller cell production of insulin-like growth factor binding proteins in vitro: modulation with phenotype and growth factor stimulation. Invest Ophthalmol Vis Sci. 2004;45:4535-4542.
50. Pfeiffer A, Spranger J, Meyer-Schwickerath R, Scatz H. Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes. 1997;46(suppl 2):S26-S30.
51. Grant M, Russel B, Fitzgerald C, Merimee T. Insulin-like growth factors in vitreous: studies in control and diabetic subjects with neovascularization. Diabetes. 1986;35:416-420.
52. Spranger J, Mohlig M, Osterhoff M, Buhnen J, Blum WF, Pfeiffer AF. Retinal photocoagulation does not influence intraocular levels of IGF- I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy-evidence for combined treatment of PDR with somatostatin analogues and retinal photocoagulation? Horm Metab Res. 2001;33:312-316.
53. 1 integrin by means of itsArg-Gly-Asp sequence. Proc Natl Acad Sci USA. 1993;90:10553-10557.
54. Irwin JC, Giudice LC. Insulin-like growth factor binding protein-1 binds to placental cytotrophoblast α5β1 integrin and inhibits cytotrophoblast invasion into decidualized endometrial stromal cultures. Growth Horm IGF Res. 1998;8:21-31.
55. Gleeson LM, Chakraborty C, McKinnon T, Lala PK. Insulin-like growth factor-binding protein 1 stimulates human trophoblast migration by signaling through α5β1 integrin via mitogen-activated protein kinase pathway. J Clin Endocrinol Metab. 2001;86:2484-2493.
56. Arnold DR, Moshayedi P, Schoen TJ, Jones BE, Chader GJ, Waldbillig RJ. Distribution of IGF-I and -II, IGF binding proteins (IG-FBPs) and IGFBP mRNA in ocular fluids and tissues: potential sites of synthesis of IGFBPs in aqueous and vitreous. Exp Eye Res. 1993;56:555-565.
57. Schoen TJ, Beebe DC, Clemmons DR, Chader GJ, Waldbillig RJ. Local synthesis and developmental regulation of avian vitreal insulin- like growth factor-binding proteins: a model for independent regulation in extravascular and vascular compartments. Endocrinology. 1992;131:2846-2854.
58. Boulton M, Gregor Z, McLeod D, et al. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol. 1997;81:228-233.
59. Yang H, Chaum E. A reassessment of insulin-like growth factor binding protein gene expression in the human retinal pigment epithelium. J Cell Biochem. 2003;89:933-943.
60. Moriarty P, Boulton M, Dickson A, McLeod D. Production of IGF-I and IGF binding proteins by retinal cells in vitro. Br J Ophthalmol. 1994;78:638-642.
61. Martin DM, Yee D, Feldman EL. Gene expression of the insulin-like growth factors and their receptors in cultured human retinal pigment epithelial cells. Brain Res Mol Brain Res. 1992;12:181-186.
62. Campochiaro PA, Hackett SF, Vinores SA, et al. Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells. J Cell Sci. 1994;107:2459-2469.